Company Introduction

Founded in 2014, AnnJi Pharmaceutical Co., Ltd. (AnnJi) is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy’s disease, or SBMA (Spinal and bulbar muscular atrophy).
 
Our goals are to translate and develop unique, innovative, and highly differentiated drug therapies and to engage global collaborators and business partners in late-stage product development and commercialization.

Brief description of main products or services 

Main Product	Indication	Description	Clinical Development
AJ101	acne vulgaris androgen and AR-related skin disorders	AJ101 is a topical cream formulation, and its active ingredient is a novel androgen receptor degradation enhancer that effectively decreased the level of androgen receptor (AR). In addition, AJ101 displayed anti-inflammatory/antioxidant properties and reduced the expression of extracellular matrix (ECM) proteins in fibroblasts.	Completed Phase 2 clinical trials in the US and Taiwan.
AJ201	spinal and bulbar muscular atrophy (SBMA)/Kennedy’s Disease neurodegenerative diseases associated with protein aggregations	AJ201 is a new chemical entity activating heat shock factor 1 (Hsf1), ubiquitin proteasome system (UPS) system, and nuclear factor erythroid 2-related factor 2 (Nrf2) pathways. In an animal model of SBMA, AJ201 alleviated behavioral defects in motor functions and ameliorated muscle atrophy,	Granted 3 FDA orphan drug designations to AJ201 for the treatments of SBMA, HD and SCA. Phase 1 clinical trial in healthy volunteers is ongoing and anticipated to be completed in the first half of 2021.
AJ302	chemotherapy-induced peripheral neuropathy (CIPN)	AJ302 is a novel selective histone deacetylase 6 inhibitor (HDAC6i). AJ302 promotes neurite outgrowth and branching in paclitaxel-induced dorsal root ganglion (DRG) neurons in vitro. In a rat model of CIPN, AJ302 was shown to reverse paclitaxel-induced mechanical allodynia in a dose-dependent manner. The improvement in sensory functions was sustained after the treatment stopped.	IND submission to US FDA Phase 1 clinical trial to be initiated in 2021
AJ303	idiopathic pulmonary fibrosis (IPF) other fibrotic diseases	AJ303 is a novel first-in-class compound with anti-fibrotic and anti-inflammatory properties. AJ303 was shown to decrease the levels of inflammatory cytokines, epithelial-mesenchymal transition markers, as well as extracellular matrix (ECM) proteins. In bleomycin-induced rodent models of IPF, AJ303 was shown to reduce the levels of TGF-b and IL-6 in the bronchoalveolar lavage fluid and the fibrotic lesions (scars) in lung.	IND in preparation